A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Amgen
Seqker Biosciences, Inc.
University Hospital, Lille
Institut Paoli-Calmettes
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Institut Claudius Regaud
Institut Claudius Regaud
Alume Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Tasly Pharmaceutical Group Co., Ltd
Asan Medical Center
ImmunityBio, Inc.
Nanjing Leads Biolabs Co.,Ltd
Boehringer Ingelheim
University of Alabama at Birmingham
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
Ondokuz Mayıs University
Abramson Cancer Center at Penn Medicine
University of California, San Diego
University of Rochester
Defactum, Central Denmark Region
Gustave Roussy, Cancer Campus, Grand Paris
Massachusetts General Hospital
Nova Scotia Health Authority
University of Alabama at Birmingham
Centre Oscar Lambret
Centre Oscar Lambret
Columbia University
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Sultan Qaboos University
Centre Hospitalier Universitaire de Besancon
H. Lee Moffitt Cancer Center and Research Institute
Linkoeping University
Varian, a Siemens Healthineers Company
University of Texas Southwestern Medical Center
AstraZeneca
Fred Hutchinson Cancer Center
Inmune Bio, Inc.
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Institute of Oncology Ljubljana
Boehringer Ingelheim
Roswell Park Cancer Institute
University Hospital, Akershus
The University of Texas at Arlington